The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Mutations of the catalytic subunit a of PI3K (PIK3CA) in erlotinib-treated non-small cell lung cancer (NSCLC) patients (p) with epidermal growth factor receptor (EGFR) mutations.
E. Carcereny
No relevant relationships to disclose
M. A. Molina
No relevant relationships to disclose
J. J. Sanchez
No relevant relationships to disclose
J. Bertran-Alamillo
No relevant relationships to disclose
C. Mayo
No relevant relationships to disclose
E. Aldeguer
No relevant relationships to disclose
A. Gimenez Capitan
No relevant relationships to disclose
Z. Yeste
No relevant relationships to disclose
C. Costa
No relevant relationships to disclose
S. Benlloch
No relevant relationships to disclose
A. Martinez
No relevant relationships to disclose
C. Buges
No relevant relationships to disclose
J. Bosch
No relevant relationships to disclose
D. Isla
No relevant relationships to disclose
M. Domine
No relevant relationships to disclose
M. Provencio
No relevant relationships to disclose
J. M. Sanchez
No relevant relationships to disclose
C. Camps
No relevant relationships to disclose
M. Taron
No relevant relationships to disclose
R. Rosell
No relevant relationships to disclose